venue - cancer r&d 2020 | cancer conferences | cancer ... · session i cancer drug development...

VenueRadisson Hotel Baltimore Downtown-Inner Harbor

101 W Fayette St, Baltimore, MD 21201, USA

https://unitedscientificgroup.com/conferences/cancer-research-drug-development/

08:00-08:20 Registrations & Welcome Coffee @ Promenade

08:20-08:30 Introduction by Dr. Sudhakar Yakkanti, Vice-President, United Scientific Group, TX @ Promenade

Keynote Talks @ International ABC

08:30-09:00 Goodbye Hospitals: Hello Implantable Sensors for Cancer Treatment Thomas Webster, Northeastern University, MA

09:00-09:30 Regulatory Mechanisms and Pharmacology of RAS Signaling at the Membrane Ruth Nussinov, NCI/NIH, MD

09:30-10:00 Maintaining Intracellular Acid-Base Homeostasis is Probably at the Core of Cancer Formation, Progression and Metastasis

Ying Xu, University of Georgia, GA

10:00-10:30 Exloiting a ‘Kiss of Death’ Therapy Using Nanotherapy-Delivered NQO1 Bioactivatable Drugs for Nonsmall Cell Lung, Pancreatic and Breast Cancer

David Boothman, Simon Cancer Center, IN

10:30-10:45 Coffee Break and Networking @ Promenade

10:45-11:15 On the Futility of Killing Cancer Cells to Cure Cancer Indraneel (Neel) Mittra, Tata Memorial Research Center, India

11:15-11:45 Somatic Mutations in HLA-class I and Other Immune Escape Genes Michael Dean, NCI/NIH, MD

11:45-12:15 Transcript Expression Patterns Predict Survival in Multiple Cancers Edward V. Prochownik, Children’s Hospital of Pittsburgh of UPMC, PA

12:15-12:45 TBA Polly Matzinger, NIAID/NIH, MD

12:45-13:45 Lunch @ International DF

13:45-14:15 Regulation of Monocyte Macrophage Maturation: Impact on Tumor Immunotherapy Dennis Klinman, NCI/NIH (Retired), MD

14:15-14:45 Harnessing Genetic Interactions to Advance Whole Exome Precision Cancer Treatment Eytan Ruppin, NCI/NIH, MD

14:45-15:15 Toward Improving mTOR-Targeted Cancer Therapies X.F. Steven Zheng, Rutgers Cancer Institute of New Jersey, NJ

15:15-15:45 Recurrent Fusion Genes in Human Cancers: Biological Roles and Opportunity of Targeting Jianhua Luo, University of Pittsburgh, PA


Session I Cancer Drug Development and Nanomedicine @ International ABC

Chair: Aditi Banerjee, University of Maryland School of Medicine, MD

16:00-16:20 The Design and Synthesis of Selective CDK4/6 Targeted PROTACs Joseph M. Salvino, The Wistar Institute, PA

16:20-16:40 Small Molecule AKR1C3 Inhibitors Circumvent Cancer Drug Resistance Paul C. Trippier, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, NE

October 21, 2019Day- 1 Monday

Day

-1

2

16:40-17:00 Concurrent Dual Cancer Stem Cell Pathways Inhibition Enhance Chemotherapy Sensitivity Mohammad O. Hoque, Johns Hopkins University School of Medicine, MD

17:00-17:20 Multifunctional and Multicomponent Nanomedicine Platform for Inhalation Treatment of Lung Cancer

Tamara Minko, Rutgers, The State University of New Jersey, NJ

17:20-17:40 A Novel miRNA-peptide Nanoparticle-Hydrogel Composite Attenuates Mesothelioma Tumor Growth

Anand Singh, NCI/NIH, MD

17:40-18:00 Non-alcoholic Steatohepatitis-Associated HCC: Potential Strategy for Prevention Yan Li, University of Louisville School of Medicine, Louisville, KY

18:00-19:00 Poster Session @ Promenade

18:00-19:00 Reception @ Promenade

Day

-1

3

Poster Presentations @ Promenade

P-01 High-throughput Screen Identifies Novel Combinations Targeting Drug-Resistant Multiple Myeloma Tyler Peat, NCI/NIH, MD

P-02 CD44 Intracellular Domain Interaction with Runx2 Regulates Prostate Cancer Metastasis Linda T. Senbanjo, University of Maryland School of Medicine, MD

P-03 Inverse Relation Between Foxm1 and Rassf1A as a Therapeutic Target of Colon Cancer Neha Sharda and Fahad Mubariz, University of Maryland, MD

P-04 Panaxynol as a Potential Ulcerative Colitis Therapeutic Hossam Tashkandi, University of South Carolina, SC

P-05 In-vitro Tested Derivatives of ONC201 can have an Antitumor Effect in Pancreatic and in Colorectal Cancer Cell Lines

Angela Takacs, Semmelweis University, Hungary

P-06 Disparities in Healthcare Utilization among Patients with Four Common Cancers, Maryland and West Virginia, 2005 and 2014

Sean Fleming, University of Maryland, Baltimore, MD

P-07 Immunomodulation as a Target using Molecules Extracted from Brazilian Spider Venom: New Perspectives for the Treatment of Cancer

Jaqueline de Lima Munhoz, University of Campinas- UNICAMP, Brazil

P-08 Mettl3 Promoted Autophagy in Epithelial Ovarian Cancer Changyu Zhu, Sichuan Provincial People’s Hospital, China

P-09 The Relativity of Genetic Polymorphisms to Plasma Methotrexate Levels and Toxicities of High-Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia

Xia He, Sichuan Provincial People’s Hospital, China

P-10 miRNAs-C19MC Regulate the Proliferation, Invasion and Migration in SKBR3 Cell Lines Andres Felipe Aristizabal Pachon, Pontifical Javeriana University, Colombia

P-11 ONC201 Induces the Unfolded Protein Response (UPR) in High and Low Grade Ovarian Carcinoma Cell Lines and Leads to Cell Death Regardless of Platinum Sensitivity

Marufa Rumman, Wayne State University, MI

P-12 Novel Stimuli-Responsive Polymeric Drug Delivery System for Doxorubicine David Vetvicka, 1st Faculty of Medicine, Charles University, Czech Republic

P-13 Development of a Zebrafish Model to Study ATP-Binding Cassette Transporters at the Blood-Brain Barrier Robert W. Robey, NCI/NIH, MD

Day

-1

4

Parallel Session -I

Parallel Session -II

Parallel Session -III

@ International A

@ International B

@ International C

Session II Novel Therapeutic Targets in Cancer

Session III Cancer Metastasis & Resistance

Session IV Cancer Targeted Therapy

Session V Cancer Immunotherapy

Symposium: Multi Drug Resistance

Session VI Cancer Genetics

October 22, 2019Day- 2 Tuesday

Day

-2

5

Session II Novel Therapeutic Targets in Cancer @ International A

Chairs: Stan Lipkowitz, NCI/NIH, MD Sooryanarayana Varambally, University of Alabama at Birmingham, AL

08:00-08:20 Treatment With an Oral Progesterone Receptor Modulator Halts Tumor Progression and Provides a Significant Increase in Longevity and Quality of Life in Patients with a Variety of Advanced Treatment-Resistant Cancers

Jerome H. Check, Cooper Institute for Reproductive Hormonal Disorders, P.C, NJ

08:20-08:40 Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy Against AML

Cihangir Duy, Weill Cornell Medicine, NY

08:40-09:00 Trop2 as a Driver and Therapeutic Target for Metastatic Castration Resistant Prostate Cancer with Neuroendocrine Phenotype

Tanya Stoyanova, Stanford University, CA

09:00-09:20 Non-Coding Micro RNAs and Hypoxia-Inducible Factors are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma—Bench-to-Bedside Therapy

Youcef M. Rustum, Roswell Park Comprehensive Cancer Center, NY

09:20-09:40 Identifying and Validating Therapeutic Targets in Cancer Using Integrated Data Analysis Tool UALCAN

Sooryanarayana Varambally, University of Alabama at Birmingham, AL

09:40-10:00 Anti-Tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

Andy Fedoriw, Cancer Epigenetics Research Unit, GlaxoSmithKline, PA

10:00-10:20 The Many Faces of the Proline Regulatory Axis in Cancer: Opportunities and Challenges James M. Phang, NCI/NIH, MD


10:40-11:00 MEDI3039, a Novel Highly Potent Tumor Necrosis Factor (TNF)-related Apoptosis-Inducing Ligand (TRAIL) Receptor 2 Agonist for the Treatment of Triple Negative Breast Cancer

Stan Lipkowitz, NCI/NIH, MD

11:00-11:20 “Real World” Survey of Hydrogen-Controlled Cancer: Follow-Up Report of 82 Cases of Advanced Cancer with Hydrogen Inhalation

Kecheng Xu, Fuda Cancer Hospital, Jinan University, China

11:20-11:40 Untreatable Terminal Advanced Prostate Cancer is Manifested by Prolactin. The First Case Report of a Successful Treatment by Employing Cabergoline

Leslie C. Costello, University of Maryland, Greenebaum Comprehensive Cancer Center, MD

11:40-12:00 Decreased Zinc in the Development and Progression of Malignancy: An Important Common Relationship and Potential for Prevention and Treatment of Carcinomas

Renty B. Franklin, University of Maryland School of Dentistry, MD

12:00-12:20 A Family of PIKFYVE Inhibitors with Therapeutic Potential against Autophagy-Dependent Cancer Cells Disrupt Multiple Events in Lysosome Homeostasis

Melvin L. DePamphilis, NICHD/NIH, MD

October 22, 2019Day- 2 Tuesday

Parallel Session -1

Day

-2

6

12:20-12:40 A Common Cellular and Molecular Pathway for Tumor Stem Cell Development Jian-Xin Gao, Shanghai Jiao Tong University School of Medicine, China

12:40-13:00 The Long Non-Coding RNA AC011445.1 as a Novel Target for Treatment of Ovarian Cancer Selin Oncul, MD Anderson Cancer Center, The University of Texas, TX


Session III Cancer Metastasis & Resistance @ International A

Chairs: John Tarbell, The City College of New York, NY Meenakshi A. Chellaiah, University of Maryland, School of Dentistry, MD

14:00-14:20 Role of Angiopoietin-Like 4 Protein in Head and Neck Squamous Cell Carcinoma Metastasis through Lymphangiogenesis

Silvia Montaner, University of Maryland School of Dentistry, MD

14:20-14:40 CD44 Regulates the Maintenance of Stemness and Progression of Cancer through Sox2 Expression in Androgen-Independent Prostate Cancer Cells (Pc3 Cells) Derived from Bone Metastasis

Meenakshi A. Chellaiah, University of Maryland, School of Dentistry, MD

14:40-15:00 Tracing Breast Cancer Stem Cell Plasticity Using Dual E/M Fluorescent Reporters Ming Luo, University of Michigan, MI

15:00-15:20 Fate-mapping Hypoxic Cells to Determine their Role in Metastasis Daniele Gilkes, The Johns Hopkins University School of Medicine, MD

15:20-15:40 Cancer Cell Glycocalyx Mediates Renal Carcinoma Metastasis John Tarbell, The City College of New York, NY

15:40-16:00 IMPACT Abrogates Metastatic Outgrowth of Pancreatic Cancer Cells in the Liver through Inhibition of Gcn1-Atf4 Signaling at Physiologic Glutamine

Surajit Sinha, NCI/NIH, MD


16:20-16:40 S100A4 Promotes TNBC Metastasis by MMP-9 Upregulation Ashakumary Lakshmikuttyamma, Thomas Jefferson University, PA

16:40-17:00 The Interaction of Tumor Cells and Astrocytes Promotes Breast Cancer Brain Metastases through Transforming Growth Factor-Beta2/Angiopoietin-like 4 Axes

Ling Wang, Medical College of Wisconsin, WI

17:00-17:20 Effects of Surfactants on Water Solubility and Anti-hepatic Fibrosis of Curcuminoids Hongtao Xiao, University of Electronic Science and Technology, China

17:20-17:40 EGFR Naivety in Epithelial Lung Cancer Stem Cells Contributes to TKI Resistance in Non-small Cell Lung Cancer

Zhiguang Xiao, University of Rochester, NY

17:40-18:00 Developing Resistance Mechanism Based Predictive Biomarker for Topoisomerase I Inhibitors Ajit Bharti, Boston University Medical School, MA

Day

-2

7

Session IV Cancer Targeted Therapy @ International B

Chairs: Yekaterina Zaytseva, University of Kentucky, KY Waldemar Debinski, Wake Forest School of Medicine, NC

08:00-08:20 GPCR Regulate RTK Transactivation in a Reactive Oxygen Species Dependent Manner Terry W. Moody, NIH/NCI, MD

08:20-08:40 Targeted Osmotic Lysis of Advanced-Stage Cancers Using Concurrent Pulsed Magnetic Fields and Pharmacological Blockade of Sodium Pumps

Dennis Paul, Louisiana State University, Health Sciences Center, LA

08:40-09:00 Multivalent Agents for Targeting Glioblastoma Waldemar Debinski, Wake Forest School of Medicine, NC

09:00-09:20 Polyamine Depletion as a Therapeutic Strategy for MYCN-driven Neuroblastoma Murray Norris, Children’s Cancer Institute, Australia

09:20-09:40 Towards a Mitochondria-Based-Targeted Therapy for Eliminating Chemoresistant Tumor-initiating (Stem) Cells

Kasturi Mitra, University of Alabama, AL

09:40-10:00 AvidinOX and Biotinylated Therapeutics: Targeting the Cure Where it is Needed Rita De Santis, Alfasigma SpA, Italy

10:00-10:20 Wnt5a Signaling Pathways and Regulatory Mechanisms in Microenvironment of Disease-Implications for Therapeutic Approaches

Ramiro Malgor, Ohio University, OH

10:20-10:40 Targeting the SHP2 Tyrosine Phosphatase to Antagonize JAK2 Inhibitor Persistence in Myeloproliferative Neoplasms

Gary W. Reuther, Moffitt Cancer Center, FL


10:55-11:15 Inhibition of Angiogenic Signaling Upregulates Rassf1A Expression Aditi Banerjee, University of Maryland School of Medicine, MD

11:15-11:35 Cancer Cells Exhibit Selective Vulnerabilities to a Novel Small Molecule Degrader of HERP1 Protein

Wenjing Yan, University of Maryland, School of Medicine, MD

11:35-11:55 Fatty Acid Synthase as a Therapeutic Target for Colorectal Cancer Yekaterina Zaytseva, University of Kentucky, KY

11:55-12:15 Targeted Chemotherapy Combined with Doxorubicin Reduces Growth and Viability of Immunoresistant CT26 Colorectal Tumors and Alters the Tumor Microenvironment

Irving W. Wainer, University of Rowan, Cooper Medical School, NJ

12:15-12:35 In vitro Radiosensitizing Effects of Proteasome Inhibitor Bortezomib through Pdl-1 Expression on 3D Glioblastoma Cell Cultures

Betul Karademir, School of Medicine, University of Marmara, Turkey

12:35-12:55 Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy Xingming Deng, Emory University, GA

12:55-13:15 Targeting Hsp90 in Type 1 Papillary Renal Cell Cancer Roma Pahwa, NCI/NIH, MD

Parallel Session -11

Day

-2

8

13:15-13:35 Partial Agonist Action of Cetuximab on Epidermal Growth Factor Receptor Hakan Gurdal, Ankara University, Turkey


Session V Cancer Immunotherapy @ International B

Chairs: Stephen J Beebe, Old Dominion University, VA Jie Xu, MD Anderson Cancer Center, TX

14:15-14:35 ALT-803 Enhances Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Mediated by NEO-201 against Human Carcinoma Cells

Kwong Y. Tsang and Massimo Fantini, Precision Biologics, Inc., MD

14:35-14:55 IDO2 Targeting in Pancreatic Cancer George C. Prendergast, President and CEO, Lankenau Institute for Medical Research, PA

14:55-15:15 Beta-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD1 Therapy in Hepatocellular Carcinoma

Amaia Lujambio, Icahn School of Medicine at Mount Sinai, NY

15:15-15:35 Integration of Oncogenes via Sleeping Beauty as a Mouse Model of HPV16+ Oral Tumors and Immunologic Contro

Chien-Fu Hung, Johns Hopkins University, MD

15:35-15:55 REGN4018, a Mucin 16 Bispecific T Cell Engaging Antibody for the Treatment of Ovarian Cancer Alison Crawford, Regeneron Pharmaceuticals, Inc., NY


16:10-16:30 Translational Research with Nanosecond Pulse Stimulation for Immuno-Oncology Applications Stephen J. Beebe, Old Dominion University, VA

16:30-16:50 Activation of CD206 in Tumor-associated Macrophages Restores Immune Surveillance and Triggers Anti-tumor Immune Responses

Juan Marugan, NCATS/NIH, MD

16:50-17:10 Histiocytic and Dendritic Cell Neoplasms: Potential Targets for PD-1 Blockage Therapy Jie Xu, MD Anderson Cancer Center, TX

17:10-17:30 Targeting Glycosylated Pd-L1 in Triple-Negative Breast Cancer Seung-Oe Lim, Purdue University, IN

17:30-17:50 Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas Jing Hong Wang, University of Colorado, CO

17:50-18:10 Nano-enabled Cancer Immunotherapy via Concurrently Triggering Immunogenic Cell Death and Suppressing the Immune Checkpoints

Jianqin Lu, University of Arizona, AZD

ay-2

9

Symposium Multi Drug Resistance: Linking Fundamental Mechanisms to Clinical Applications through Innovation and Multidisciplinary Approaches

Chairs: Suresh V. Ambudkar, NCI/NIH, MD Anika M.S. Hartz, University of Kentucky, KY

08:00-08:10 Introduction Talk by Dr. Suresh V. Ambudkar

08:10-08:40 Probing the Clinical Relevance of Mechanisms of Multidrug Resistance in Cancer Michael M. Gottesman, NCI/NIH, MD

08:40-09:10 ABC Transporters and Drug Resistance: Molecular Basis of Polyspecificity Suresh V. Ambudkar, NCI/NIH, MD

09:10-09:40 Dual Pi3K/Akt Inhibition: A New Strategy to Improve Drug Delivery in Glioblastoma Therapy Anika M.S. Hartz, University of Kentucky, KY

09:40-10:10 ABCC4, A Transporter with a Role in Cancer and Improving Drug Therapy John D. Schuetz, St. Jude Children’s Research Hospital, TN

10:10-10:40 Overcoming Multidrug Resistance in Cancers by Natural Products Zhe-Sheng (Jason) Chen, St. John’s University, NY


11:00-11:30 ABC Transporters in Clinical Drug Resistance Revisited Susan E. Bates, Columbia University Medical Center, NY

11:30-12:00 Transporter Polymorphism in Drug Discovery: A Company Perspective Yan Zhang, Associate Director, Incyte Corporation, WE

12:00-12:20 Shedding New Light on the inhibition of ATP-Binding Cassette Transporters Huang Chiao (Joe) Huang, University of Maryland, MD

12:20-12:40 4E-BP1 as an Oncogenic/Therapeutic Target Qing-Bai She, University of Kentucky, KY

12:40-13:00 Novel Caspase-independent Inducers to Target Triple Negative Form of Breast Cancer Amit K. Tiwari, University of Toledo, OH


Session VI Cancer Genetics @ International C

Chairs: Teresa Przytycka, NCI/NIH, MD Kazimierz O Wrzeszczynski, New York Genome Center, NY

14:00-14:20 Enhancer Signatures and Loss of Swi/Snf Function in Cell Lines from Human Metastatic Bladder Cancer

Gordon L. Hager, NCI/NIH, MD

14:20-14:40 Targeting the WRN Helicase-Nuclease in vivo with Small Molecules Robert M. Brosh, Jr NIA/NIH, MD

14:40-15:00 Genomic Profiling using Clinical Whole Genome and Transcriptome Sequencing to Enable Precision Oncology

Kazimierz O. Wrzeszczynski, New York Genome Center, NY

Parallel Session -111

Day

-2

10

@ International C

15:00-15:20 microRNA - Induced Protein Truncation via DNA Binding Melanie Von Brandenstein, University Hospital of Cologne, Germany

15:20-15:40 Role of Aging Related DNA Methylation Dynamics in Shaping Tumor Development Hariharan Easwaran, Johns Hopkins University, MD


16:00-16:20 Computational Identification of Drug Sensitivity Subnetworks Teresa Przytycka, NCI/NIH, MD

16:20-16:40 Epigenetic Reprogramming Strategies in High-Grade Serous Ovarian Cancer Daniela M. Dinulescu, Harvard Medical School, MA

16:40-17:00 pathCHEMO: Uncovering Pathway Markers of Chemoresistance in Lung Adenocarcinoma Antonina Mitrofanova, Rutgers University, The State University of New Jersey, NJ

17:00-17:20 Optimizing CRISPR Tools for High-Throughput Screening Joana A. Vidigal, NIH/NCI, MD

17:20-17:40 Genomic and Transcriptomic Characterization Links Cell Lines with Aggressive Head and Neck Cancers from TCGA

Zhong Chen, NIDCD/NIH, MD

17:40-18:00 Glimps: Glioblastoma Immune Prognostic Signature Associated with Response to Anti-PD1 Immunotherapy

Shaoli Das, NIH/NCI, MD

18:00-18:20 The Role of FOXM1 Transcription Factor in the Maintenance of Leukemia Stem Cells Zhijian Qian, University of Florida, FL

Day

-2

11

Session VII Organ Specific Cancers @ International AB

Chairs: Beverly A. Mock, NCI/NIH, MD Alison Crawford, Regeneron Pharmaceuticals, Inc., NY

08:00-08:20 Senescence after Growth Arrest: A Physiological Mechanism by Which Cdk4/6 Inhibitors can Exert their Anti-Tumor Effects

Andrew Koff, Memorial Sloan Kettering Cancer Center, NY

08:20-08:40 Lung Cancer-Cell Signaling Drives Immunosuppressive Responses in the Tumor Microenvironment Yinling Hu, NCI/NIH, MD

08:40-09:00 Cooperative Targeting of Mouse Tumor Susceptibility Genes Leads to Drug Combinations Targeting MYC

Beverly A. Mock, NCI/NIH, MD

09:00-09:20 Systems Approach Reveals Metabolic Reprogramming Driven Mechanism in Models of Proteasome Inhibitor Resistance

Snehal M. Gaikwad, NCI/NIH, MD

09:20-09:40 Roles of p53-Repressed Genes in the Survival of Osteosarcoma Cell Jing Huang, NCI/NIH, MD

09:40-10:00 Development of a Clinically and Genetically Relevant Metastasis Model for Osteosarcoma Yu-Chou Tseng, NCI/NIH, MD

10:00-10:20 High-throughput Screen Identifies Novel Combinations Targeting Drug-resistant Multiple Myeloma Tyler Peat, NCI/NIH, MD


10:35-10:55 Tumor Suppressive Role of Cysteine Dioxygenase 1 in Non-small Cell Lung Cancer Yun-Pyo Kang, H Lee Moffitt Cancer Center, FL

10:55-11:15 Role of CXCR4 in the Pathogenesis of Hematological Malignancies and Neuroblastoma Peled Amnon, Hadassah Hebrew University Hospital, Israel

11:15-11:35 The Transcription Factor CBFB Suppresses Breast Cancer through Orchestrating Translation and Transcription

Navdeep Malik, NCI/NIH, MD

11:35-11:55 Extracellular Signaling and Communication Between Liver Cancer Cells and Neighboring Cells Ayse Mine Yilmaz, Marmara University, Turkey

11:55-12:15 Identifying Novel Biomarkers Predictive of Response to ATR and CHK1 inhibitors Junran Zhang, Ohio State University, OH

12:15-12:35 Comparison of Fixed Versus Traditional Weight-based Dosing of Rasburicase in a Pediatric Population

Radha Rohatgi, Childrens National Medical Center, Washington, DC

12:35-12:55 Fluorescent Reporters for Simultaneous Determination of Cell Cycle Phase and Onset of Cell Death

Yongliang Zhang, NIDDK/NIH, MD

12:55-14:00 Lunch & Departures @ International DF

October 23, 2019Day- 3 Wednesday

Day

-3

12

USG-United Scientific Group (A non-profit scientific organization)

# 8105, Rasor Blvd - Suite #112, PLANO, TX 75024, USA

Phone: +1-408-426-4832/33 | Toll-free: 844-395-4102

Fax: 408-426-4869

Email: [email protected]

Web: https://unitedscientificgroup.com/conferences/cancer-research-drug-development/

venue - cancer r&d 2020 | cancer conferences | cancer ... · session i cancer drug development...

Documents